188 related articles for article (PubMed ID: 34293596)
1. Neurotransmitters and Neuropeptides decrease PD-1 in T cells of healthy subjects and patients with hepatocellular carcinoma (HCC), and increase their proliferation and eradication of HCC cells.
Levite M; Safadi R; Milgrom Y; Massarwa M; Galun E
Neuropeptides; 2021 Oct; 89():102159. PubMed ID: 34293596
[TBL] [Abstract][Full Text] [Related]
2. T Cells Plead for Rejuvenation and Amplification; With the Brain's Neurotransmitters and Neuropeptides We Can Make It Happen.
Levite M
Front Immunol; 2021; 12():617658. PubMed ID: 33868232
[TBL] [Abstract][Full Text] [Related]
3. Towards neuroimmunotherapy for cancer: the neurotransmitters glutamate, dopamine and GnRH-II augment substantially the ability of T cells of few head and neck cancer patients to perform spontaneous migration, chemotactic migration and migration towards the autologous tumor, and also elevate markedly the expression of CD3zeta and CD3epsilon TCR-associated chains.
Saussez S; Laumbacher B; Chantrain G; Rodriguez A; Gu S; Wank R; Levite M
J Neural Transm (Vienna); 2014 Aug; 121(8):1007-27. PubMed ID: 25030361
[TBL] [Abstract][Full Text] [Related]
4. Neuro faces of beneficial T cells: essential in brain, impaired in aging and neurological diseases, and activated functionally by neurotransmitters and neuropeptides.
Levite M
Neural Regen Res; 2023 Jun; 18(6):1165-1178. PubMed ID: 36453390
[TBL] [Abstract][Full Text] [Related]
5. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.
Chen J; Ji T; Zhao J; Li G; Zhang J; Jin R; Liu J; Liu X; Liang X; Huang D; Xie A; Lin H; Cang Y; Cai X
Oncotarget; 2016 Jul; 7(27):41274-41284. PubMed ID: 27129180
[TBL] [Abstract][Full Text] [Related]
7. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
8. Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma.
Guo L; Li H; Fan T; Ma Y; Wang L
Life Sci; 2021 Aug; 279():119359. PubMed ID: 33753114
[TBL] [Abstract][Full Text] [Related]
9. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors.
Levite M
Curr Opin Pharmacol; 2008 Aug; 8(4):460-71. PubMed ID: 18579442
[TBL] [Abstract][Full Text] [Related]
10. Dual-Targeted Autoimmune Sword in Fatal Epilepsy: Patient's glutamate receptor AMPA GluR3B peptide autoimmune antibodies bind, induce Reactive Oxygen Species (ROS) in, and kill both human neural cells and T cells.
Levite M; Zelig D; Friedman A; Ilouz N; Eilam R; Bromberg Z; Ramadhan Lasu AA; Arbel-Alon S; Edvardson S; Tarshish M; Riek LP; Lako RL; Reubinoff B; Lebendiker M; Yaish D; Stavsky A; Galun E
J Autoimmun; 2020 Aug; 112():102462. PubMed ID: 32561150
[TBL] [Abstract][Full Text] [Related]
11. Programmed Cell Death 1 and Hepatocellular Carcinoma: An Epochal Story.
Demirtas CO; Gunduz F
J Gastrointest Cancer; 2021 Dec; 52(4):1217-1222. PubMed ID: 34897577
[TBL] [Abstract][Full Text] [Related]
12. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.
Di Blasi D; Boldanova T; Mori L; Terracciano L; Heim MH; De Libero G
Cell Mol Gastroenterol Hepatol; 2020; 9(2):195-218. PubMed ID: 31445190
[TBL] [Abstract][Full Text] [Related]
13. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma.
Zhang PF; Gao C; Huang XY; Lu JC; Guo XJ; Shi GM; Cai JB; Ke AW
Mol Cancer; 2020 Jun; 19(1):110. PubMed ID: 32593303
[TBL] [Abstract][Full Text] [Related]
14. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
Li G; Liu D; Cooper TK; Kimchi ET; Qi X; Avella DM; Li N; Yang QX; Kester M; Rountree CB; Kaifi JT; Cole DJ; Rockey DC; Schell TD; Staveley-O'Carroll KF
J Hepatol; 2017 Jan; 66(1):75-85. PubMed ID: 27520877
[TBL] [Abstract][Full Text] [Related]
15. Expression Profiles of Neuropeptides, Neurotransmitters, and Their Receptors in Human Keratocytes In Vitro and In Situ.
Słoniecka M; Le Roux S; Boman P; Byström B; Zhou Q; Danielson P
PLoS One; 2015; 10(7):e0134157. PubMed ID: 26214847
[TBL] [Abstract][Full Text] [Related]
16. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
Han Y; Chen Z; Yang Y; Jiang Z; Gu Y; Liu Y; Lin C; Pan Z; Yu Y; Jiang M; Zhou W; Cao X
Hepatology; 2014 Feb; 59(2):567-79. PubMed ID: 23960017
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy.
Nikoo M; Hassan ZF; Mardasi M; Rostamnezhad E; Roozbahani F; Rahimi S; Mohammadi J
Pathol Res Pract; 2023 Jul; 247():154473. PubMed ID: 37207558
[TBL] [Abstract][Full Text] [Related]
18. Lineage-specific regulation of PD-1 expression in early-stage hepatocellular carcinoma following 90yttrium transarterial radioembolization - Implications in treatment outcomes.
Núñez KG; Sandow T; Gimenez J; Hibino M; Fort D; Cohen AJ; Thevenot PT
Eur J Cancer; 2024 Jan; 196():113442. PubMed ID: 37988841
[TBL] [Abstract][Full Text] [Related]
19. Glutamate, T cells and multiple sclerosis.
Levite M
J Neural Transm (Vienna); 2017 Jul; 124(7):775-798. PubMed ID: 28236206
[TBL] [Abstract][Full Text] [Related]
20. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
